GlobeNewswire

Open Source Strategy Forum Announces 2018 Event in London and Opens Call for Papers

Dela

PALO ALTO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Symphony Software Foundation (the Foundation), the nonprofit organization fostering open source software innovation in financial services, will be hosting its second Open Source Strategy Forum on November 14, 2018. Following a successful 2017 event at BNY Mellon in New York City, the Open Source Strategy Forum moves this year to London, another global epicenter of financial services and the fintech revolution. The Call For Papers and Sponsor  Application links are open today.

Last year's inaugural event attracted over 300 attendees from the world's leading financial services institutions, fintechs, integrators, and vendors. The program featured keynotes from thought leaders across open source and financial services, 28 presentations, and several interactive panel sessions. It featured industry-leading speakers such as Amber Baldet (J.P. Morgan), Jim Jagielski (Capital One, The Apache Software Foundation), John Stecher (Barclays), whurley (William Hurley of Goldman Sachs), Heather Meeker (O'Melveny & Myers), Nithya Ruff (Comcast), Cynthia Rich (GitHub), and Joe McCann (NodeSource).

This year, OSSF maintains its focus on executives, senior technologists, and compliance professionals from financial services firms seeking to drive innovation through open source. It will also expand its focus to engage financial services developers consuming, building, and contributing to open source technology. Abundant networking time will be built into the schedule to foster collaboration and community building.

Attendees will hear from financial technology leaders about how to leverage open source to accelerate their business goals. They'll also learn how to implement best practices for open source collaboration, integrate open source into the enterprise software supply chain, and overcome the technical and compliance hurdles unique to financial services. The event is produced by the Symphony Software Foundation, which has a diverse membership across financial services institutions and platform organizations, as well as proven experience in facilitating open source innovation in financial services.

"Adopting the open source methodology is only a part of the equation. Like in any change management process, business value ultimately drives decisions at all levels. It's only when executives realize the "why"-the true potential of leveraging open source in furthering their business strategy-that fruitful open source engagement will happen," said Gabriele Columbro, Executive Director, Symphony Software Foundation. "This year's Open Source Strategy Forum will bring together Wall Street leaders and the grassroots developer community to make that engagement a reality, marrying the needs of the modern technical workforce with the requirements of decision-makers."

Jim Jagielski, Co-Founder and Vice Chairman, Apache Software Foundation, said, "This event is an important and increasingly vital opportunity for financial services to obtain real-world knowledge related to consuming and contributing back to open source software under unique fintech conditions. Last year's inaugural event was a supreme success and filled a long-standing void in the finserv ecosystem by focusing directly on the issues and solutions applicable to that community. As financial services companies drive towards innovation and a true digital strategy, the Open Source Strategy Forum is the premier, 'go-to' conference and a 'must-attend' event."

The Open Source Strategy Forum hosts talks from bank executives, open source and enterprise thought leaders, and experienced attorneys. Sessions will range from short TED-style talks to longer, in-depth sessions related to both business and technology strategy challenges, as well as developer content on innovative open source fintech technologies.

Sign up for updates on the Open Source Strategy Forum and submit a Call For Papers and Sponsor  ApplicationEmail us at press@symphony.foundation for more details.

About Symphony Software Foundation

The Symphony Software Foundation is an independent non­profit organization building an open source community and development ecosystem to foster innovation in financial services. Its community leverages Symphony, open source platforms, and open standards to drive efficient inter-firm collaboration in this industry. The Foundation offers an Open Developer Platform (ODP) to all its open source contributors, providing open API access to Symphony and a compliant open source development process.

Foundation OSS Projects are Apache 2.0 licensed and available on GitHub

To access the ODP, visit our documentation

To learn more about OSSF, visit opensourcestrategyforum.org

To become a member symphony.foundation/#become-a-member

Photos accompanying this announcement are available at

http://www.globenewswire.com/NewsRoom/AttachmentNg/497bcbe5-4b23-464b-96e7-d5e552f86d9e

http://www.globenewswire.com/NewsRoom/AttachmentNg/60ca70fc-b1b4-4851-9a83-2d50e6ffbf5e

For more information: 
On behalf of Symphony Software Foundation
Tinne Teugels
Email: tinne@symphony.foundation press@symphony.foundationCall: +1 (646) 520 5548




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Symphony Software Foundation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum